Table 3 List of biobanks of different tumor types
From: Organoid based personalized medicine: from bench to bedside
Organ of origin | Number of lines a | Histological subtypes | Efficiency | Year | Ref. |
|---|---|---|---|---|---|
Colon | 22 | Adenocarcinomas | 90% | 2015 | (van de Wetering et al. 2015) |
Colorectum | 8 | Colorectal metastases | 71% | 2015 | (Weeber et al. 2015) |
Colorectum | 55 | Premalignant lesions (tubular and tubulovillous adenomas, sessile serrated lesions, and a hyperplastic polyp) Adenocarcinomas (well differentiated, moderately differentiated, poorly differentiated, mucinous, not specified) Metastases of adenocarcinomas Neuroendocrine carcinomas | 100% | 2016 | (Fujii et al. 2016) |
Colorectum | 35 | NR | 60% | 2017 | (Schütte et al. 2017) |
Colorectum | 34 | Colorectal metastases | 63% | 2019 | (Ooft et al. 2019) |
Rectum | 71 | Cystic fibrosis | NR | 2016 | (Dekkers et al. 2016) |
Rectum | 65 | Adenocarcinoma | 77% | 2019 | (Ganesh et al. 2019) |
Rectum | 80 | locally advanced rectal adenocarcinoma | 85.7% | 2019 | (Yao et al. 2020) |
Pancreas | 8 | Ductal adenocarcinomas | 80% | 2015 | (Boj et al. 2015) |
Pancreas | 17 | Ductal adenocarcinomas | 85% | 2015 | (Huang et al. 2015b) |
Pancreas | 39 | Ductal adenocarcinomas | 88% | 2018 | (Seino et al. 2018) |
Pancreas | 114 | Ductal adenocarcinomas | 75% | 2018 | (Tiriac et al. 2018) |
Pancreas | 30 | Pancreatic ductal adenocarcinoma Acinar cell carcinoma Cholangiocarcinoma Adenosquamous Pancreatic ductal adenocarcinoma Intraductal papillary mucinous neoplasm-derived Pancreatic ductal adenocarcinoma Papilla of Vater adenocarcinoma | 60% | 2019 | (Driehuis et al. 2019c) |
Liver | 8 | Hepatocellular carcinoma Cholangiocellular carcinoma | 100% | 2017 | (Broutier et al. 2017) |
Liver | 13 | Hepatocellular carcinomaCholangiocellular carcinomaLymphoepithelioma-like cholangiocarcinoma | 33% | 2017 | (Nuciforo et al. 2018) |
Biliary Tract | 6 | Intrahepatic cholangiocarcinomaPancreatic ductal adenocarcinomaGallbladder cancerNeuroendocrine carcinoma | 42% | 2019 | (Saito et al. 2019) |
Prostate | 7 | Adenocarcinoma metastases Circulating tumor cells | 15-20% | 2014 | (Gao et al. 2014) |
Bladder | 22 | Papillary urothelial carcinomaUrothelial carcinomaSquamous cell carcinoma | 70% | 2018 | (Lee et al. 2018) |
Breast | 95 | Ductal carcinoma Lobular carcinoma | 80% | 2018 | (Sachs et al. 2018) |
Ovary | 33 | High-grade serous carcinoma | 100% | 2018 | (Hill et al. 2018) |
Ovary | 56 | Borderline tumors (both mucinous and serous) Clear cell carcinomas Endometrioid carcinomas Mucinous carcinomas Low-grade serous carcinomas High-grade serous carcinomas | 65% | 2019 | (Kopper et al. 2019) |
Head and Neck | 31 | Squamous cell carcinoma | 60 | 2019 | (Driehuis et al. 2019a) |
Brain | 70 | Glioblastoma | 91.4% | 2020 | (Jacob et al. 2020) |
Mixedb | 56 | Tumors from prostate, breast, colorectal, esophagus, brain, pancreas, lung, small intestine, ovary, uterus, soft tissue (not further specified), bladder, ureter, kidney | 38.6% | 2017 | |
Mixed | 62 | Metastatic colorectal cancer Metastatic gastroesophageal cancer Metastatic cholangiocarcinoma | 70% | 2018 | (Vlachogiannis et al. 2018) |
Mixed (ALI) | 49 | Tumors from lung (adenocarcinoma and squamous cell carcinoma), kidney (clear cell carcinoma, papillary carcinoma, Wilms tumor and chromophobe carcinoma) and thyroid (papillary carcinoma) | 76% | 2018 | (Neal et al. 2018) |